Comprehensive multi-omic analyses of "islands of resistance" tumour cells to identify aromatase inhibitor resistant subclones in ER+ breast cancer

对“耐药岛”肿瘤细胞进行全面的多组学分析，以鉴定 ER 乳腺癌中芳香酶抑制剂耐药的亚克隆

• 批准号: 2893229
• 金额: --
• 依托单位: Institute of Cancer Research
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2893229
• 关键词: Comprehensive; multi; omic; analyses; islands

Aromatase Inhibitor (AI) treatment is the most effective therapy for post-menopausal women with early oestrogen receptor positive (ER+) breast cancer. Changes of Ki67 value after short-term neoadjuvant AI is a measure of tumour's early response to AI. Some proliferating cells remain in most ER+ cancers after treatment and these cells may be responsible for the outgrowth of resistant clones. This PhD project will focus on discovering the genomic changes that are specific to these resistant clones to provide a better understanding of why these cells did not response to AI and may allow additional personalised treatment targeting these resistant cells.

芳香化酶抑制剂（AI）治疗是绝经后女性早期雌激素受体阳性（ER+）乳腺癌的最有效疗法。短期新辅助AI后Ki67值的变化是肿瘤对AI的早期反应的量度。一些增殖细胞在治疗后保留在大多数ER+癌症中，这些细胞可能是耐药克隆生长的原因。该博士项目将专注于发现这些耐药克隆特有的基因组变化，以更好地了解为什么这些细胞对AI没有反应，并可能允许针对这些耐药细胞的额外个性化治疗。